BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price

BBOTStock
$9.37+3.39%52W
Market Cap$751.23M
P/E86.81x
PEG Ratio
Div yield
Beta0.38

BBOT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-25.91%
Price vs S&P 500 (4W)3.35%
VGM Score43.65
P/E Ratio (Annual)86.81x

BBOT Earnings Surprise History

Q2 25-50.36est.
Q3 25-1.03est. -0.34
Q4 25-0.49est. -0.66
Q2 26-0.71est. -0.54

BBOT Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.31
4.31
4.29

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock
DC$9.37
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About BridgeBio Oncology Therapeutics, Inc. Common Stock

BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing cancer therapies that target RAS and PI3Ka mutations, two of the most frequently mutated oncogenic drivers. The company aims to address unmet needs in oncology by creating targeted treatments for patients with these genetically-driven cancers.